Rosen L - Search Results

1

First-in-human clinical outcomes with NG-350A, an anti-CD40 expressing tumor-selective vector designed to remodel immunosuppressive tumor microenvironments.

Naing A, Khalil D, Rosen O, Camidge DR, Lillie T, Ji RR, Stacey A, Thomas M, Rosen L. Naing A, et al. Among authors: rosen l. J Immunother Cancer. 2024 Oct 15;12(10):e010016. doi: 10.1136/jitc-2024-010016. J Immunother Cancer. 2024. PMID: 39414325 Free PMC article. Clinical Trial.

2

Safety and efficacy of the tumor-selective adenovirus enadenotucirev, in combination with nivolumab, in patients with advanced/metastatic epithelial cancer: a phase I clinical trial (SPICE).

Fakih M, Harb W, Mahadevan D, Babiker H, Berlin J, Lillie T, Krige D, Carter J, Cox C, Patel M, Parfitt L, Powell M, Rosen L. Fakih M, et al. Among authors: rosen l. J Immunother Cancer. 2023 Apr;11(4):e006561. doi: 10.1136/jitc-2022-006561. J Immunother Cancer. 2023. PMID: 37094988 Free PMC article. Clinical Trial.

3

First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies.

Papadopoulos KP, Johnson ML, Lockhart AC, Moore K, Falchook GS, Formenti SC, Naing A, Carvajal RD, Rosen LS, Weiss GJ, Leidner RS, Li J, Paccaly A, Feng M, Stankevich E, Lowy I, Fury MG, Crittenden MR. Papadopoulos KP, et al. Among authors: rosen ls. Clin Cancer Res. 2020 Mar 1;26(5):1025-1033. doi: 10.1158/1078-0432.CCR-19-2609. Epub 2019 Dec 3. Clin Cancer Res. 2020. PMID: 31796520 Clinical Trial.

4

Phase I study of BIIB028, a selective heat shock protein 90 inhibitor, in patients with refractory metastatic or locally advanced solid tumors.

Hong D, Said R, Falchook G, Naing A, Moulder S, Tsimberidou AM, Galluppi G, Dakappagari N, Storgard C, Kurzrock R, Rosen LS. Hong D, et al. Clin Cancer Res. 2013 Sep 1;19(17):4824-31. doi: 10.1158/1078-0432.CCR-13-0477. Epub 2013 Jul 19. Clin Cancer Res. 2013. PMID: 23873691 Free PMC article. Clinical Trial.

5

Phase II trial of irinotecan in combination with amifostine in patients with advanced colorectal carcinoma.

Delioukina ML, Prager D, Parson M, Hecht JR, Rosen P, Rosen LS. Delioukina ML, et al. Among authors: rosen ls, rosen p. Cancer. 2002 Apr 15;94(8):2174-9. doi: 10.1002/cncr.10432. Cancer. 2002. PMID: 12001114 Free article. Clinical Trial.

6

Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib.

Goldman JW, Laux I, Chai F, Savage RE, Ferrari D, Garmey EG, Just RG, Rosen LS. Goldman JW, et al. Cancer. 2012 Dec 1;118(23):5903-11. doi: 10.1002/cncr.27575. Epub 2012 May 17. Cancer. 2012. PMID: 22605616 Free article. Clinical Trial.

7

Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors.

Johnson FM, Agrawal S, Burris H, Rosen L, Dhillon N, Hong D, Blackwood-Chirchir A, Luo FR, Sy O, Kaul S, Chiappori AA. Johnson FM, et al. Among authors: rosen l. Cancer. 2010 Mar 15;116(6):1582-91. doi: 10.1002/cncr.24927. Cancer. 2010. PMID: 20108303 Free article. Clinical Trial.

8

Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases.

Berenson JR, Rosen LS, Howell A, Porter L, Coleman RE, Morley W, Dreicer R, Kuross SA, Lipton A, Seaman JJ. Berenson JR, et al. Among authors: rosen ls. Cancer. 2001 Apr 1;91(7):1191-200. doi: 10.1002/1097-0142(20010401)91:7<1191::aid-cncr1119>3.0.co;2-0. Cancer. 2001. PMID: 11283917 Clinical Trial.

9

PF-06952229, a selective TGF-β-R1 inhibitor: preclinical development and a first-in-human, phase I, dose-escalation study in advanced solid tumors.

Yap TA, Choudhury AD, Hamilton E, Rosen LS, Stratton KL, Gordon MS, Schaer D, Liu L, Zhang L, Mittapalli RK, Zhong W, Soman N, Tolcher AW. Yap TA, et al. Among authors: rosen ls. ESMO Open. 2024 Sep;9(9):103653. doi: 10.1016/j.esmoop.2024.103653. Epub 2024 Aug 29. ESMO Open. 2024. PMID: 39214047 Free PMC article. Clinical Trial.

10

A phase I dose-escalation trial of trastuzumab and alvespimycin hydrochloride (KOS-1022; 17 DMAG) in the treatment of advanced solid tumors.

Jhaveri K, Miller K, Rosen L, Schneider B, Chap L, Hannah A, Zhong Z, Ma W, Hudis C, Modi S. Jhaveri K, et al. Among authors: rosen l. Clin Cancer Res. 2012 Sep 15;18(18):5090-8. doi: 10.1158/1078-0432.CCR-11-3200. Epub 2012 Jul 10. Clin Cancer Res. 2012. PMID: 22781552 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,226 results

Search Page

Filters